Zeteletinib
Appearance
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H23F3N4O4 |
Molar mass | 500.478 g·mol−1 |
3D model (JSmol) | |
| |
|
Zeteletinib (BOS-172738, DS-5010) is an experimental anticancer medication which acts as a RET inhibitor.[1][2]
See also
[edit]References
[edit]- ^ Vodopivec DM, Hu MI (2022). "RET kinase inhibitors for RET-altered thyroid cancers". Therapeutic Advances in Medical Oncology. 14: 17588359221101691. doi:10.1177/17588359221101691. PMC 9218446. PMID 35756966.
- ^ Gou Q, Gan X, Li L, Gou Q, Zhang T (December 2022). "Precious Gene: The Application of RET-Altered Inhibitors". Molecules (Basel, Switzerland). 27 (24): 8839. doi:10.3390/molecules27248839. PMC 9784389. PMID 36557971.